Your browser doesn't support javascript.
loading
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino, Mattia; Cairns, David A; Lahuerta, Juan José; Wester, Ruth; Bertsch, Uta; Waage, Anders; Zamagni, Elena; Mateos, María-Victoria; Dall'Olio, Daniele; van de Donk, Niels W C J; Jackson, Graham; Rocchi, Serena; Salwender, Hans; Bladé Creixenti, Joan; van der Holt, Bronno; Castellani, Gastone; Bonello, Francesca; Capra, Andrea; Mai, Elias K; Dürig, Jan; Gay, Francesca; Zweegman, Sonja; Cavo, Michele; Kaiser, Martin F; Goldschmidt, Hartmut; Hernández Rivas, Jesús María; Larocca, Alessandra; Cook, Gordon; San-Miguel, Jesús F; Boccadoro, Mario; Sonneveld, Pieter.
Affiliation
  • D'Agostino M; SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
  • Cairns DA; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Lahuerta JJ; Instituto de Investigación del Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Wester R; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Bertsch U; University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Waage A; Institute of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • Zamagni E; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Bologna, Italy.
  • Mateos MV; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
  • Dall'Olio D; Complejo Asistencial Universitario de Salamanca/IBSAL/CIC/Ciberonc, Salamanca, Spain.
  • van de Donk NWCJ; Dipartimento di Fisica e Astronomia, Università di Bologna, Bologna, Italy.
  • Jackson G; Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Rocchi S; University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.
  • Salwender H; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Bologna, Italy.
  • Bladé Creixenti J; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
  • van der Holt B; Asklepios Tumorzentrum Hamburg, AK Altona and AK St Georg, Hamburg, Germany.
  • Castellani G; Hospital Clinic, IDIBAPS, Barcelona, Spain.
  • Bonello F; HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Capra A; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
  • Mai EK; SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
  • Dürig J; SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
  • Gay F; University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Zweegman S; Department of Hematology, University Clinic Essen, Essen, Germany.
  • Cavo M; SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
  • Kaiser MF; Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Goldschmidt H; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Bologna, Italy.
  • Hernández Rivas JM; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
  • Larocca A; The Institute of Cancer Research, London, United Kingdom and The Royal Marsden Hospital, London, United Kingdom.
  • Cook G; University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • San-Miguel JF; Department of Medicine, University of Salamanca, Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca-Cancer Research Center of Salamanca (IBMCC, USAL-CSIG). Hematology Department, Hospital Universitario de Salamanca (CAUSA/IBSAL), Salamanca, Spain.
  • Boccadoro M; SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
  • Sonneveld P; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
J Clin Oncol ; 40(29): 3406-3418, 2022 10 10.
Article in En | MEDLINE | ID: mdl-35605179
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Clin Oncol Year: 2022 Document type: Article Affiliation country: Italy Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Clin Oncol Year: 2022 Document type: Article Affiliation country: Italy Country of publication: United States